name: immunoglobulin heavy constant gamma 1 deaminated 5 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been deaminated on the residue at the position equivalent to Asn-84 of the amino acid sequence represented by UniProtKB:P01857-2. Example: UniProtKB:P01857-2, Asn-84, MOD:00684.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 48 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G85740DB. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G85740DB.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 9 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan structure is represented by GlyTouCan:G11254FL. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G11254FL.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 31 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G59937CP. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G59937CP.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 20 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G40834TG. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G40834TG.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 11 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan structure is represented by GlyTouCan:G22674CI. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G22674CI.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 22 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G45504EY. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G45504EY.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 28 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G57317CE. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G57317CE.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 46 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G83646BJ. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G83646BJ.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 24 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G50073PQ. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G50073PQ.


name: immunoglobulin heavy constant gamma 1 deaminated 9 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been deaminated on the residue at the position equivalent to Asn-267 of the amino acid sequence represented by UniProtKB:P01857-2. Example: UniProtKB:P01857-2, Asn-267, MOD:00684.


name: immunoglobulin heavy constant gamma 1 deaminated 6 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been deaminated on the residue at the position equivalent to Gln-269 of the amino acid sequence represented by UniProtKB:P01857-2. Example: UniProtKB:P01857-2, Gln-269, MOD:00685.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 43 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan structure is represented by GlyTouCan:G80858MF. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G80858MF.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 42 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G80475RE. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G80475RE.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 49 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G88374WZ. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G88374WZ.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 2 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G02815KT. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G02815KT.


name: immunoglobulin heavy constant gamma 1 isoform h2 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P01857-2.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 27 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G72787SB. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G72787SB.


name: immunoglobulin heavy constant gamma 1 deaminated 4 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been deaminated on the residue at the position equivalent to Asn-244 of the amino acid sequence represented by UniProtKB:P01857-2. Example: UniProtKB:P01857-2, Asn-244, MOD:00684.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 19 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan structure is represented by GlyTouCan:G39213VZ. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G39213VZ.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 15 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G28603RA. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G28603RA.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 4 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G57776ZU. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G57776ZU.


name: immunoglobulin heavy constant gamma 1 deaminated 8 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been deaminated on the residue at the position equivalent to Asn-272 of the amino acid sequence represented by UniProtKB:P01857-2. Example: UniProtKB:P01857-2, Asn-272, MOD:00684.


name: immunoglobulin heavy constant gamma 1 isoform h1 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P01857-1.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 1 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G00912UN. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G00912UN.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 45 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G83633GK. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G83633GK.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 26 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G54600FO. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G54600FO.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 41 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan structure is represented by GlyTouCan:G78059CC. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G78059CC.


name: immunoglobulin heavy constant gamma 1 N-glycosylated 12 (human)

description: An immunoglobulin heavy constant gamma 1 (human) that has been N-glycosylated at the residue equivalent to Asn-180 of the amino acid sequence represented by UniProtKB:P01857-2, in which the glycan composition is represented by GlyTouCan:G25079LO. Example: UniProtKB:P01857-2, Asn-180, MOD:00160~GNO:G25079LO.


name: eIF-2-alpha kinase GCN2 isoform h1 (human)

description: An eIF-2-alpha kinase GCN2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9P2K8-1.


name: bifunctional phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase isoform 1 (human)

description: A bifunctional phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase isoform 1 that is encoded in the genome of human.


A cadherin that is a translation product of the human CDH15 gene or a 1:1 ortholog thereof.


name: serine/threonine-protein kinase Nek2 isoform h3 (human)

description: A serine/threonine-protein kinase Nek2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P51955-3.


phosphatidylcholine O-38:7

A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 38 carbons and 7 double bonds.


name: transmembrane protein 126A acetylated 1 (human)

description: A transmembrane protein 126A that is N-terminal Met acetylated in human. Example: UniProtKB:Q9H061-1, Met-1, MOD:00058.


A FAHFA obtained by formal condensation of the carboxy group of palmitic acid with the hydroxy group of 7-hydroxystearic acid.


dickkopf-like protein 1

A protein that is a translation product of the human DKKL1 gene or a 1:1 ortholog thereof.


Small forehead

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: The presence of a forehead that is abnormally small.


Narrow forehead

description: Width of the forehead or distance between the frontotemporales is more than two standard deviations below the mean (objective); or apparently narrow intertemporal region (subjective).


Segmental peripheral demyelination

description: A loss of myelin from the internode regions along myelinated nerve fibers from segments of the peripheral nervous system.


name: Patchy demyelination of subcortical white matter

description: Patchy loss of myelin from nerve fibers in the central nervous system.


name: Abnormal central microtubular pair morphology of respiratory motile cilia

description: A structural anomaly of the two central microtubules of motile cilia with a 9+2 microtubuluar configuration.


name: Absent central microtubular pair morphology of respiratory motile cilia

description: Absence of the two central microtubules of motile cilia with a 9+2 microtubuluar configuration.


name: Symmetrical progressive peripheral demyelination

description: A symmetric and progressive loss of myelin from the internode regions along myelinated nerve fibers of the peripheral nervous system.


name: Diffuse demyelination of the cerebral white matter

description: A diffuse loss of myelin from nerve fibers in the central nervous system.


name: Abnormal respiratory motile cilium morphology

description: Abnormal arrangement of the structures of the motile cilium.


description: A segmental pattern of demyelination and regeneration (remyelination) affecting peripheral nerves.


Symmetric peripheral demyelination

description: A symmetric loss of myelin from the internode regions along myelinated nerve fibers of the peripheral nervous system.


Asymmetric peripheral demyelination

description: Loss of myelin from peripheral nerves in a pattern that differs between right and left.


name: Spinal cord posterior columns myelin loss


Decreased dendritic spine number

description: An abnormal reduction in the amount of spines on a given dendrite.


Absent inner dynein arms

description: Absence of the inner dynein arms of respiratory motile cilia, which normally are situated within the peripheral microtubules of motile cilia. This feature is usually appreciated by electron microscopy.


Absent inner and outer dynein arms

description: Complete absence of the dynein arms of respiratory motile cilia, that is, absence of the inner and the outer dynein arms, which normally are situated inside and outside of the peripheral microtubules of motile cilia. This feature is usually appreciated by electron microscopy.


Abnormal neuron branching

description: Abnormality of the structure and branching of the dendrites of a neuron.


Diffuse peripheral demyelination

description: A diffuse loss of myelin from the internode regions along myelinated nerve fibers of the peripheral nervous system.


name: Dynein arm defect of respiratory motile cilia

description: An anomaly of the dynein arms of motile cilia. This feature is usually appreciated by electron microscopy.


name: Severe demyelination of the white matter

description: A severe loss of myelin from nerve fibers in the central nervous system.


Absent outer dynein arms

description: Absence of the outer dynein arms of respiratory motile cilia, which normally are situated outside of the peripheral microtubules of motile cilia. This feature is usually appreciated by electron microscopy.


name: Absent respiratory ciliary axoneme radial spokes

description: Absence of the radial spokes of the axoneme of the respiratory cilium.


name: vitamin K-dependent protein C N-glycosylated 25 (human)

description: A vitamin K-dependent protein C (human) that has been N-glycosylated at the residue equivalent to Asn-355 of the amino acid sequence represented by UniProtKB:P04070-1, in which the glycan structure is represented by GlyTouCan:G42440OJ. Example: UniProtKB:P04070-1, Asn-355, MOD:00160~GNO:G42440OJ.


name: huntingtin-interacting protein 1 deaminated 1 (human)

description: A huntingtin-interacting protein 1 (human) that has been deaminated on the residue at the position equivalent to Gln-200 of the amino acid sequence represented by UniProtKB:O00291-1. Example: UniProtKB:O00291-1, Gln-200, MOD:00685.


rhotekin phosphorylated 1 (human)

A rhotekin (human) that has been phosphorylated on the residue at the position equivalent to Thr-465 of the amino acid sequence represented by UniProtKB:Q9BST9-1. Example: UniProtKB:Q9BST9-1, Thr-465, MOD:00047.


anthocyanidin 3-O-beta-D-galactoside

An anthocyanidin D-galactoside having the galactosyl residue at the 3-position attached via a beta-linkage.


name: cell division cycle protein 27 homolog deaminated 1 (human)

description: A cell division cycle protein 27 homolog (human) that has been deaminated on the residue at the position equivalent to Gln-326 of the amino acid sequence represented by UniProtKB:P30260-1. Example: UniProtKB:P30260-1, Gln-326, MOD:00685.


uromodulin N-glycosylated 389 (human)

A uromodulin (human) that has been N-glycosylated at the residue equivalent to Asn-80 of the amino acid sequence represented by UniProtKB:P07911-1, in which the glycan structure is represented by GlyTouCan:G33241WC. Example: UniProtKB:P07911-1, Asn-80, MOD:00160~GNO:G33241WC.


Stage II Urethral Cancer AJCC v7

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: Stage II includes: T2, N0, M0.  T2: Tumor invades any of the following: corpus spongiosum, prostate, periurethral muscle.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Urethral Cancer by AJCC v7 Stage

description: A term that refers to the staging of urethral cancer according to the American Joint Committee on Cancer, 7th edition.


Stage I Urethral Cancer AJCC v7

description: Stage I includes: T1, N0, M0.  T1: Tumor invades subepithelial connective tissue.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)


Stage 0 Urethral Cancer AJCC v7

description: Stage 0 includes: 0a (Ta, N0, M0); 0is (Tis, N0, M0); (Tis pu, N0, M0); (Tis pd, N0, M0).  Ta: Noninvasive papillary, polypoid, or verrucous carcinoma.  Tis: Carcinoma in situ.  Tis pu: Carcinoma in situ, involvement of the prostatic urethra.  Tis pd: Carcinoma in situ, involvement of the prostatic ducts.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


carcinoma in situ of urethra

description: A in situ carcinoma that involves the urethra.


Stage IV Urethral Cancer AJCC v7

description: Stage IV includes: (T4, N0, M0); (T4, N1, M0); (Any T, N2, M0), (Any T, Any N, M1).  T4: Tumor invades other adjacent organs.  N0: No regional lymph node metastasis.  N1: Metastasis in a single lymph node 2 cm or less in greatest dimension.  N2: Metastasis in a single lymph node more than 2 cm in greatest dimension, or in multiple lymph nodes.  M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)


Stage 0a Urethral Cancer AJCC v7

description: Stage 0a includes: Ta, N0, M0.  Ta: Noninvasive papillary, polypoid, or verrucous carcinoma.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Urethral Cancer AJCC v7

description: Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, N0, M0), (T3, N1, M0).  T1: Tumor invades subepithelial connective tissue.  T2: Tumor invades any of the following: corpus spongiosum, prostate, periurethral muscle.  T3: Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, anterior vagina, bladder neck.  N1: Metastasis in a single lymph node 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


name: Gallbladder Undifferentiated Carcinoma, Spindle and Giant Cell Type

description: An undifferentiated carcinoma that arises from the gallbladder.  It is characterized by the presence of spindle and giant malignant cells, including osteoclast-like giant cells.


name: cellular tumor antigen p53 sequence variant K132* (human)

description: A cellular tumor antigen p53 (human) that has has been truncated after the position equivalent to Asn-131 of the amino acid sequence represented by UniProtKB:P04637-1. Example: UniProtKB:P04637-1, 1-131.


name: E3 ubiquitin-protein ligase DTX1 cysteinylated 1 (human)

description: An E3 ubiquitin-protein ligase DTX1 (human) that has been cysteinylated on the residue at the position equivalent to Cys-349 of the amino acid sequence represented by UniProtKB:Q86Y01. UniProtKB:Q86Y01, Cys-349, MOD:00765.


E3 ubiquitin-protein ligase DTX1

A protein that is a translation product of the human DTX1 gene or a 1:1 ortholog thereof.


description: A rare primary bone dysplasia disorder characterized by congenital hypotrichosis associated with rhizomelic short stature (more pronounced in upper limbs than lower limbs), limited hip abduction and mild genu varum. Flared and irregular metaphyses, delayed and irregular epiphiseal ossification and pear-shaped vertebral bodies are characteristic radiologic findings.


name: aggrecan core protein O-glycosylated 84 (human)

description: An aggrecan core protein (human) that has been O-glycosylated at the residue equivalent to Thr-2223 of the amino acid sequence represented by UniProtKB:P16112-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:P16112-1, Thr-2223, MOD:00005~GNO:G53434XO.


Optic ataxia

description: Difficulty reaching visually guided goals in peripheral vision, with the deficit, leaves voluntary eye movements largely unaffected.


name: alpha-fetoprotein N-glycosylated 13 (human)

description: An alpha-fetoprotein (human) that has been N-glycosylated at the residue equivalent to Asn-251 of the amino acid sequence represented by UniProtKB:P02771-1, in which the glycan structure is represented by GlyTouCan:G43694RQ. Example: UniProtKB:P02771-1, Asn-251, MOD:00160~GNO:G43694RQ.


name: E3 ubiquitin-protein ligase NEDD4-like isoform h2 (human)

description: An E3 ubiquitin-protein ligase NEDD4-like (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96PU5-2.


name: N-acetylmuramoyl-L-alanine amidase O-glycosylated 9 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been O-glycosylated at the residue equivalent to Thr-182 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:Q96PD5-1, Thr-182, MOD:00005~GNO:G43417UB.


name: N-acetylmuramoyl-L-alanine amidase N-glycosylated 3 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been N-glycosylated at the residue equivalent to Asn-485 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan structure is represented by GlyTouCan:G42358LZ. Example: UniProtKB:Q96PD5-1, Asn-485, MOD:00160~GNO:G42358LZ.


name: N-acetylmuramoyl-L-alanine amidase isoform h2 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96PD5-2.


name: N-acetylmuramoyl-L-alanine amidase O-glycosylated 3 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been O-glycosylated at the residue equivalent to Thr-168 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:Q96PD5-1, Thr-168, MOD:00005~GNO:G29068FM.


name: N-acetylmuramoyl-L-alanine amidase O-glycosylated 8 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been O-glycosylated at the residue equivalent to Thr-182 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:Q96PD5-1, Thr-182, MOD:00005~GNO:G29068FM.


name: N-acetylmuramoyl-L-alanine amidase O-glycosylated 6 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been O-glycosylated at the residue equivalent to Thr-181 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:Q96PD5-1, Thr-181, MOD:00005~GNO:G43417UB.


name: N-acetylmuramoyl-L-alanine amidase O-glycosylated 1 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been O-glycosylated at the residue equivalent to Ser-177 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:Q96PD5-1, Ser-177, MOD:00002~GNO:G43417UB.


name: N-acetylmuramoyl-L-alanine amidase isoform h1 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96PD5-1.


name: N-acetylmuramoyl-L-alanine amidase O-glycosylated 5 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been O-glycosylated at the residue equivalent to Thr-181 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:Q96PD5-1, Thr-181, MOD:00005~GNO:G29068FM.


name: N-acetylmuramoyl-L-alanine amidase O-glycosylated 2 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been O-glycosylated at the residue equivalent to Thr-151 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:Q96PD5-1, Thr-151, MOD:00005~GNO:G43417UB.


name: N-acetylmuramoyl-L-alanine amidase O-glycosylated 10 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been O-glycosylated at the residue equivalent to Thr-193 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:Q96PD5-1, Thr-193, MOD:00005~GNO:G29068FM.


name: N-acetylmuramoyl-L-alanine amidase O-glycosylated 7 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been O-glycosylated at the residue equivalent to Thr-181 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:Q96PD5-1, Thr-181, MOD:00005~GNO:G53434XO.


name: N-acetylmuramoyl-L-alanine amidase, signal peptide removed form (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has had the signal peptide removed. Example: UniProtKB:Q96PD5-1, 22-576.


name: N-acetylmuramoyl-L-alanine amidase N-glycosylated 1 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been N-glycosylated at the residue equivalent to Asn-367 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G00912UN. Example: UniProtKB:Q96PD5-1, Asn-367, MOD:00160~GNO:G00912UN.


name: N-acetylmuramoyl-L-alanine amidase N-glycosylated 2 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been N-glycosylated at the residue equivalent to Asn-367 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan structure is represented by GlyTouCan:G42358LZ. Example: UniProtKB:Q96PD5-1, Asn-367, MOD:00160~GNO:G42358LZ.


name: N-acetylmuramoyl-L-alanine amidase O-glycosylated 4 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been O-glycosylated at the residue equivalent to Thr-168 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:Q96PD5-1, Thr-168, MOD:00005~GNO:G43417UB.


name: N-acetylmuramoyl-L-alanine amidase O-glycosylated 11 (human)

description: An N-acetylmuramoyl-L-alanine amidase (human) that has been O-glycosylated at the residue equivalent to Thr-193 of the amino acid sequence represented by UniProtKB:Q96PD5-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:Q96PD5-1, Thr-193, MOD:00005~GNO:G43417UB.


A steroid compound with a structure based on a 27-carbon (cholestane) skeleton.


A C27-steroid that is cholesterol carrying a hydroxy group at position 16S and 22S.


A 3beta-hydroxy-Delta(5)-steroid that is furostan carrying a double bond between positions 5-6 and hydroxy groups at positions 3beta and 22R.


A cholestanoid that is (5alpha)-cholest-7-ene substituted by a beta-hydroxy group at position 3.


A brassinosteroid that is 6-deoxo-28-norteasterone carrying an oxo group at position 6.


An  oxysterol that is  cholesterol substituted by hydroxy groups at positions 17 and 20 (the 20R-stereoisomer).


(25R)-Delta(4)-dafachronic acid

A cholestanoid that is (5alpha,25R)-cholest-4-en-26-oic acid substituted at position 3 by an oxo group.


A C27-steroid that is cholesterol carrying a hydroxy group at position 16S and an oxo group at position 22.


A deuterated compound that is cholesterol in which the hydrogens at positions 2, 2, 3, 4, 4 and 6 are replaced by deuterium.


A cholestanoid that is 4-cholesten-3-one carrying two additional hydroxy substituents at positions 7alpha and 25.


A cholestanoid that is 7-dehydrocholesterol carrying an additional hydroxy substituent at position 24 (24S-stereoisomer).


A cholestanoid that is 7-dehydrocholesterol carrying an additional hydroxy substituent at position 25.


(25S)-Delta(4)-dafachronic acid

A Delta(4)-dafachronic acid that has S configuration at position 25 (the carbon attached to the carboxy group). Found in Caenorhabditis elegans.


An oxysterol that is cholesterol substituted by hydroxy groups at positions 17 and 20 (the 20S-stereoisomer).


A cholestanoid that is desmosterol carrying an additional hydroxy susbstituent at position 26.


Delta(4)-dafachronic acid

A cholestanoid that is cholest-4-en-26-oic acid which is substituted at position 3 by an oxo group.


A (2'->5')-dinucleotide in which the two nucleoside components connected by the (2'->5')-phosphodiester linkage are adenosine.


Bruising susceptibility

description: An ecchymosis (bruise) refers to the skin discoloration caused by the escape of blood into the tissues from ruptured blood vessels. This term refers to an abnormally increased susceptibility to bruising. The corresponding phenotypic abnormality is generally elicited on medical history as a report of frequent ecchymoses or bruising without adequate trauma.


Aplastic nasopharyngeal adenoids

description: Absence of the nasopharyngeal adenoids as a developmental defect.


name: chondrodysplasia punctata, brachytelephalangic, autosomal


name: autosomal dominant chondrodysplasia punctata

description: Autosomal dominant form of chondrodysplasia punctata.


name: chondrodysplasia punctata, tibial-metacarpal type


name: microtubule-associated serine/threonine-protein kinase 2 isoform h1 (human)

description: A microtubule-associated serine/threonine-protein kinase 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6P0Q8-1.


Broad long bones

description: Increased cross-section (diameter) of the long bones. Note that widening may primarily affect specific regions of long bones (e.g., diaphysis or metaphysis), but this should be coded separately.


Broad phalanges of the hand

description: Increased width of the phalanges of the hand.


Broad distal phalanx of the thumb

description: Increased width of the distal phalanx of thumb.


Broad 1st metacarpal

description: Increased width of the 1st metacarpal. In contrast to the proximal phalanges of the digits 2-5, the proximal phalanx of the thumb is embryologically equivalent to the middle phalanges of the other digits, whereas the first metacarpal is embryologically of phalangeal origin and as such equivalent to the proximal phalanges of the other digits.


Spatulate thumbs

description: Spoon-shaped, broad thumbs.


Broad hallux phalanx

description: An increase in width in one or more phalanges of the big toe.


Broad middle phalanx of the 4th finger

description: Increased width of the middle phalanx of the 4th finger.


Broad metatarsal

description: Increased side-to-side width of a metatarsal bone.


Broad phalanges of the 3rd finger

description: Increased width of the phalanges of the 3rd finger.


name: Broad proximal phalanx of the 3rd finger

description: Increased width of the proximal phalanx of the 3rd finger.


Broad middle phalanx of the 2nd finger

description: Increased width of the middle phalanx of the second finger.


Broad radial metaphysis

description: Increase in width (breadth) of the radial metaphysis.


Broad clavicles

description: Increased width (cross-sectional diameter) of the clavicles.


Broad distal phalanx of finger

description: Abnormally wide (broad) distal phalanx of finger.


Broad first metatarsal

description: Increased side-to-side width of the first metatarsal bone.


Broad distal phalanx of the hallux

description: An increase in width of the distal phalanx of the big toe.


Broad phalanx

description: Increased side-to-side width of one or more phalanges of the fingers or toes.


Bulbous tips of toes

description: An abnormality of the morphology of the toes, such that the tips of the toes are prominent and bulbous.


Broad phalanges of the 4th finger

description: Increased width of the phalanges of the 4th finger.


Broad phalanx of the toes

description: Increased width of phalanx of one or more toes.


Broad proximal phalanges of the hand

description: Increased width of the proximal phalanges of the finger.


Broad ulna

description: Increased width of the ulna.


Broad proximal phalanx of the hallux

description: Increased width of proximal phalanx of big toe.


Broad middle phalanx of finger

description: Increased width of the middle phalanx of finger.


Broad proximal phalanx of the thumb

description: Increased width of the proximal phalanx of the thumb. In contrast to the proximal phalanges of the digits 2-5, the proximal phalanx of the thumb is embryologically equivalent to the middle phalanges of the other digits, whereas the first metacarpal is embryologically of phalangeal origin and as such equivalent to the proximal phalanges of the other digits.


Broad distal phalanx of the 5th finger

description: Increased width of the distal phalanx of the 5th finger.


Broad metacarpals

description: Abnormally broad metacarpal bones.


name: Broad proximal phalanx of the 4th finger

description: Increased width of the proximal phalanx of the 4th finger.


Broad distal phalanx of the 4th finger

description: Increased width of the distal phalanx of the 4th finger.


name: Broad proximal phalanx of the 5th finger

description: Increased width of the proximal phalanx of the 5th finger.


name: Expanded phalanges with widened medullary cavities


Broad proximal phalanx of toe

description: An increase in width of one ore more proximal toe phalanges.


Increased fibular diameter

description: Increased width of the cross sectional diameter of the fibula.


Broad phalanges of the 5th finger

description: Increased width of the phalanges of the 5th finger.


Broad middle phalanx of the 5th finger

description: Increased width of the middle phalanx of the 5th finger.


Broad radius

description: Increased width of the radius.


Broad middle phalanx of the 3rd finger

description: Increased width of the middle phalanx of the 3rd finger.


name: Broad proximal phalanx of the 2nd finger

description: Increased width of the proximal phalanx of the 2nd finger.


Broad distal phalanx of the toes

description: Increased width of the distal phalanx of toe of one or more toes.


Broad distal phalanx of the 2nd finger

description: Increased width of the distal phalanx of the 2nd finger.


Broad distal phalanx of the 3rd finger

description: Increased width of the distal phalanx of the 3rd finger.


Broad distal phalanges of all fingers

description: Abnormally wide (broad) distal phalanx of finger of all fingers.


Broad thumb

description: Increased thumb width without increased dorso-ventral dimension.


name: leukemia inhibitory factor, signal peptide removed form (human)

description: A leukemia inhibitory factor (human) that has had the signal peptide removed. UniProtKB:P15018, 23-202.


Abnormal sixth cranial nerve morphology

description: Any structural abnormality of the abducens nerve.


abducens nerve disorder

description: A non-neoplastic or neoplastic disorder affecting the abducens nerve (sixth cranial nerve).


Sixth cranial nerve hypoplasia

description: Underdevelopment of the six cranial nerve (abducens nerve).


hemoglobin D disease

description: Hemoglobin D disease(HbD) is a hemoglobinopathy characterized by production of abnormal variant hemoglobin known as hemoglobin D, with no or mild clinical manifestations (splenomegaly, very mild anemia).


benproperine trihydrogen phosphate

A racemate comprising equimolar amounts of (R)- and (S)-benproperine trihydrogen phosphate. It is used as a cough suppressant in non-productive cough.


Pseudoseizure

description: Sudden, involuntary seizure-like attacks that, unlike epileptic seizures, are not related to electrographic ictal discharges.


name: solute carrier family 2, facilitated glucose transporter member 2 isoform h2 (human)

description: A solute carrier family 2, facilitated glucose transporter member 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P11168-2.


name: proteasome subunit alpha type-6 isoform 1 (human)

description: A proteasome subunit alpha type-6 isoform 1 that is encoded in the genome of human.


functioning pituitary gland neoplasm

description: A hormone producing pituitary gland tumor, associated with a hormonal syndrome.


TSH producing pituitary tumor

description: An adenoma or carcinoma of the anterior lobe of the pituitary gland that produces thyrotropin.


name: malignant thyroid stimulating hormone producing neoplasm of pituitary gland

description: A rare, hormonally functioning or non-functioning pituitary gland adenocarcinoma that produces thyrotropin.


name: pseudouridylate synthase TRUB2, mitochondrial isoform 1 (human)

description: A pseudouridylate synthase TRUB2, mitochondrial isoform 1 that is encoded in the genome of human.


name: Stage II Acral Lentiginous Melanoma AJCC v6 and v7

description: Stage II includes: IIA: (T2b, N0, M0); (T3a, N0, M0); IIB: (T3b, N0, M0); (T4a, N0, M0); IIC: (T4b, N0, M0).  T2b: Cutaneous melanoma with a tumor measuring 1.01-2.0 mm in thickness, with ulceration.  T3a: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, without ulceration.  T3b: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, with ulceration.  T4a: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, without ulceration.  T4b: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, with ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Ed.)


ubiquitin (RPS27A) (human)

A ubiquitin (RPS27A) in human. UniProtKB:P62979, 1-76.


name: apolipoprotein A-II O-glycosylated 1 (human)

description: An apolipoprotein A-II (human) that has been O-glycosylated at the residue equivalent to Ser-32 of the amino acid sequence represented by UniProtKB:P02652-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P02652-1, Ser-32, MOD:00002~GNO:G43417UB.


apolipoprotein A-II

A protein that is a translation product of the human APOA2 gene or a 1:1 ortholog thereof.


name: apolipoprotein A-II O-glycosylated 4 (human)

description: An apolipoprotein A-II (human) that has been O-glycosylated at the residue equivalent to Thr-42 of the amino acid sequence represented by UniProtKB:P02652-1, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:P02652-1, Thr-42, MOD:00005~GNO:G29068FM.


name: apolipoprotein A-II, signal peptide removed phosphorylated form (human)

description: An apolipoprotein A-II (human) that has had the signal peptide removed and that includes at least 1 phosphorylated residue. UniProtKB:P02652, 19-100, MOD:00696.


name: apolipoprotein A-II, signal peptide removed form (human)

description: An apolipoprotein A-II (human) that has had the signal peptide removed. UniProtKB:P02652, 19-100.


name: apolipoprotein A-II O-glycosylated 3 (human)

description: An apolipoprotein A-II (human) that has been O-glycosylated at the residue equivalent to Ser-35 of the amino acid sequence represented by UniProtKB:P02652-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:P02652-1, Ser-35, MOD:00002~GNO:G53434XO.


name: apolipoprotein A-II O-glycosylated 2 (human)

description: An apolipoprotein A-II (human) that has been O-glycosylated at the residue equivalent to Ser-35 of the amino acid sequence represented by UniProtKB:P02652-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P02652-1, Ser-35, MOD:00002~GNO:G43417UB.


name: cyclin-dependent kinase 8 isoform 1 (human)

description: A cyclin-dependent kinase 8 isoform 1 that is encoded in the genome of human.


name: serine/threonine-protein kinase tousled-like 1 isoform 1 (human)

description: A serine/threonine-protein kinase tousled-like 1 isoform 1 that is encoded in the genome of human.


name: abnormal spindle-like microcephaly-associated protein methylated 6 (human)

description: An abnormal spindle-like microcephaly-associated protein (human) that has been methylated on the residue at the position equivalent to Cys-1145 of the amino acid sequence represented by UniProtKB:Q8IZT6-1. Example: UniProtKB:Q8IZT6-1, Cys-1145, MOD:00660.


name: elongator complex protein 5 isoform h2 (human)

description: An elongator complex protein 5 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8TE02-2.


protein PML sumoylated 1 (human)

A protein PML (human) that has been sumoylated on the residues at the positions equivalent to Lys-65, Lys-160, and Lys-490 of the amino acid sequence represented by UniProtKB:P29590-1. Example: UniProtKB:P29590-1, Lys-65/Lys-160/Lys-490, MOD:01149.


name: epidermal growth factor receptor substrate 15-like 1 isoform h1 (human)

description: An epidermal growth factor receptor substrate 15-like 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBC2-1.


name: epidermal growth factor receptor substrate 15-like 1

description: A protein that is a translation product of the human EPS15L1 gene or a 1:1 ortholog thereof.


name: epidermal growth factor receptor substrate 15-like 1, initiator methionine removed form (human)

description: An epidermal growth factor receptor substrate 15-like 1 (human) that has had the initiator methionine removed. UniProtKB:Q9UBC2, 2-864.


name: epidermal growth factor receptor substrate 15-like 1 isoform h2 (human)

description: An epidermal growth factor receptor substrate 15-like 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBC2-2.


name: epidermal growth factor receptor substrate 15-like 1 isoform h3 (human)

description: An epidermal growth factor receptor substrate 15-like 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBC2-3.


name: epidermal growth factor receptor substrate 15-like 1 isoform h4 (human)

description: An epidermal growth factor receptor substrate 15-like 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBC2-4.


kininogen-1 O-glycosylated 16 (human)

A kininogen-1 (human) that has been O-glycosylated at the residue equivalent to Thr-137 of the amino acid sequence represented by UniProtKB:P01042-1, in which the glycan composition is represented by GlyTouCan:G17015OC. Example: UniProtKB:P01042-1, Thr-137, MOD:00005~GNO:G17015OC.


name: guided entry of tail-anchored proteins factor CAMLG methylated 1 (human)

description: A guided entry of tail-anchored proteins factor CAMLG (human) that has been methylated on the residue at the position equivalent to Cys-284 of the amino acid sequence represented by UniProtKB:P49069. UniProtKB:P49069, Cys-284, MOD:00660.


CD40 ligand N-glycosylated 12 (human)

A CD40 ligand (human) that has been N-glycosylated at the residue equivalent to Asn-240 of the amino acid sequence represented by UniProtKB:P29965-1, in which the glycan structure is represented by GlyTouCan:G55220VL. Example: UniProtKB:P29965-1, Asn-240, MOD:00160~GNO:G55220VL.


MINHERYIN G

An ent-kaurane diterpenoid isolated from Isodon henryi and has been shown to exhibit cytotoxic activity.


name: Cutaneous stenosis of the external auditory canal


A carboxylic ester resulting from the formal condensation of the carboxy group of isobutyric acid with the 1-hydroxy group of 2,4,4-trimethylpentane-1,3-diol.


name: Metastatic Malignant Neoplasm to the Thyroid

description: A malignant neoplasm either directly extending to the thyroid gland from adjacent structures (e.g. pharynx, larynx, esophagus, cervical lymph nodes), or spreading to the thyroid gland from distant anatomic sites, most frequently kidney, lung, uterus, breast, and skin.  The majority of cases are carcinomas, lymphomas, and melanomas.


Metastatic malignant neoplasm to neck

description: A malignant neoplasm that has spread to the neck region from a malignancy in a local or distant anatomic site.


name: Metastatic malignant neoplasm to parathyroid gland

description: A malignant neoplasm either directly extending to the parathyroid glands from adjacent anatomic structures, or spreading to the parathyroid glands from distant anatomic sites, most frequently breast, lung, kidney, soft tissues, and skin.


name: Metastatic malignant neoplasm to nasopharynx

description: A malignant neoplasm that has spread to the nasopharynx from another anatomic site.


name: Metastatic malignant neoplasm to oropharynx

description: A malignant neoplasm that has spread to the oropharynx from another anatomic site.


name: Metastatic malignant neoplasm to hypopharynx

description: A malignant neoplasm that has spread to the hypopharynx from another anatomic site.


Metastatic malignant neoplasm to larynx

description: A malignant neoplasm that has spread to the larynx from another anatomic site.


name: Neck Squamous Cell Carcinoma of Unknown Primary

description: A squamous cell carcinoma that has metastasized to the neck lymph nodes from an unknown primary anatomic site.


name: Recurrent Neck Squamous Cell Carcinoma of Unknown Primary

description: The reemergence of metastatic squamous cell carcinoma of unknown primary in the neck region after a period of remission.


name: Metastatic malignant neoplasm to pharynx

description: A malignant neoplasm that has spread to the pharynx from another anatomic site.


name: Human Papillomavirus-Related Head and Neck Squamous Cell Carcinoma of Unknown Primary

description: A squamous cell carcinoma that is associated with human papillomavirus infection and has metastasized to the neck lymph nodes from an unknown primary anatomic site.


name: Human Papillomavirus-Negative Head and Neck Squamous Cell Carcinoma of Unknown Primary

description: A squamous cell carcinoma that is not associated with human papillomavirus infection and has metastasized to the neck lymph nodes from an unknown primary anatomic site.


Verruca plana

description: Slightly raised wart 2-5 mm in diameter often associated with viral infections, commonly persistent in immunodeficient individuals.


name: protein max isoform long phosphorylated 1 (human)

description: A protein max isoform long phosphorylated 1 in human. UniProtKB:P61244-1, Ser-2/Ser-11, MOD:00046.


protein max isoform long (human)

A protein max isoform long that is encoded in the genome of human.


name: linker for activation of T-cells family member 1 isoform h3 (human)

description: A linker for activation of T-cells family member 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O43561-3.


name: linker for activation of T-cells family member 1

description: A protein that is a translation product of the human LAT gene or a 1:1 ortholog thereof.


name: linker for activation of T-cells family member 1 isoform h2 (human)

description: A linker for activation of T-cells family member 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O43561-2.


name: linker for activation of T-cells family member 1 isoform h4 (human)

description: A linker for activation of T-cells family member 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O43561-4.


name: linker for activation of T-cells family member 1 phosphorylated 2 (human)

description: A linker for activation of T-cells family member 1 (human) that has been post-translationally modified to include phosphotyrosine at positions 200 and 220 of the amino acid sequence represented by UniProtKB:O43561. UniProtKB:O43561, Tyr-200/Tyr-220, MOD:00048.


name: linker for activation of T-cells family member 1 isoform h5 (human)

description: A linker for activation of T-cells family member 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O43561-5.


name: linker for activation of T-cells family member 1 phosphorylated 1 (human)

description: A linker for activation of T-cells family member 1 (human) that has been post-translationally modified to include phosphotyrosine at positions 156, 161, 200, 220 and 255 of the amino acid sequence represented by UniProtKB:O43561. UniProtKB:O43561, Tyr-156/Tyr-161/Tyr-200/Tyr-220/Tyr-255, MOD:00048.


name: linker for activation of T-cells family member 1 isoform h1 (human)

description: A linker for activation of T-cells family member 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O43561-1.


name: linker for activation of T-cells family member 1 isoform h2 phosphorylated 1 (human)

description: A linker for activation of T-cells family member 1 isoform h2 (human) that has been phosphorylated on the residues at the positions equivalent to Tyr-127, Tyr-132, Tyr-171, Tyr-191, and Tyr-226 of the amino acid sequence represented by UniProtKB:O43561-2. UniProtKB:O43561-2, Tyr-127/Tyr-132/Tyr-171/Tyr-191/Tyr-226, MOD:00048.


myrothenone A

An alicyclic ketone which is 3-oxocyclopent-1-ene substituted by a formamido group at position 1 as well as vinyl and hydroxy groups at position 4. It is isolated from a marine derived fungus Myrothecium sp. and acts as an inhibitor of tyrosinase enzyme (EC 1.14.18.1).


TP53-target gene 5 protein

A protein that is a translation product of the human TP53TG5 gene or a 1:1 ortholog thereof.


name: TP53-target gene 5 protein phosphorylated 1 (human)

description: A TP53-target gene 5 protein (human) that has been phosphorylated on the residue at the position equivalent to Thr-262 of the amino acid sequence represented by UniProtKB:Q9Y2B4. UniProtKB:Q9Y2B4, Thr-262, MOD:00047.


Hypoplastic iris stroma

description: Underdevelopment of the stroma of iris.


name: transmembrane protease serine 13 isoform h1 (human)

description: A transmembrane protease serine 13 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9BYE2-1.


name: serum paraoxonase/arylesterase 1 isoform 1 (human)

description: A serum paraoxonase/arylesterase 1 isoform 1 that is encoded in the genome of human.


name: diphthamide biosynthesis protein 3 isoform 1 (human)

description: A DPH3 isoform 1 that is encoded in the genome of human.


name: U6 snRNA-associated Sm-like protein LSm8, initiator methionine removed form (human)

description: A U6 snRNA-associated Sm-like protein LSm8 (human) that has had the initiator methionine removed. UniProtKB:O95777, 2-96.


A hydroperoxyicosatrienoic acid that is (8Z,11Z,14Z)-icosatrienoic acid in which the hydroperoxy substituent is located at position 10.


icosanoid

Any member of the group of signalling molecules arising from oxidation of the three C20 essential fatty acids (EFAs) icosapentaenoic acid (EPA), arachidonic acid (AA) and dihomo-gamma-linolenic acid (DGLA).


19-hydroxyprostaglandin H2

A prostaglandin H that consists of prostaglandin H2 bearing an additional hydroxy substituent at position 19.


A HETE that is (5Z,8Z,12E,14Z)-icosa-5,8,12,14-tetraenoic acid substituted at position 11 by a hydroxy group.


leukotriene E3

A leukotriene that is leukotriene E4 in which the non-conjugated double bond has been reduced to a single bond.


A hydroperoxy(hydroxy)icosatetraenoic acid that is (7E,9E,11Z,13E)-icosatetraenoic acid carrying 2 hydroxy substituents at positions 5S and 6R as well as a hydroperoxy substituent at position 15S.


18-hydroxythromboxane A2

A thromboxane A that is thromboxane A2 carrying an additional hydroxy substituent at position 18.


trans-2-icosenoic acid

An icosenoic acid in which the double bond is at the 2-3 position and has E configuration.


prostaglandin D2 1-glyceryl ester

A 1-monoglyceride resulting from the condensation of the carboxy group of prostaglandin D2 with the 1-hydroxy group of glycerol.


An 11-HETE in which the chiral centre at position 11 has R-configuration.


Ab 8,15-DiHETE that is derived from (5Z,9E,11Z,13E)-icosatetraenoic acid and has (8S,15S)-stereochemistry.


A hydroperoxy fatty acid that is (14R,15S)-epoxy-(6E,8Z,11Z)-icosatrienoic acid in which the hydroperoxy group is located at position 5S.


An EpETE obtained by formal epoxidation of the 17,18-double bond of all-cis-5,8,11,14,17-icosapentaenoic acid.


A bis(hydroperoxy)icosatetraenoic acid that is (6E,8Z,11Z,13E)-icosatetraenoic acid in which the two hydroperoxy groups are located at positions 5S and 15S.


6-trans-leukotriene B4

A leukotriene that is the 6-trans-isomer of leukotriene B4.


An epoxy(hydroxy)icosatrienoic acid that is the (8S,9S)-epoxy-(10R)-hydroxy derivative of icosa-(5Z,11Z,14Z)-trienoic acid.


An icosanoid that is (5Z,9E,11Z,13E)-icosatetraenoic acid carrying two hydroperoxy substituents at positions 8 and 15 (the 8S,15S-stereoisomer).


A DHET obtained by formal dihydroxylation across the 8,9-double bond of arachidonic acid.


prostaglandin E2 2-glyceryl ester

A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin E2 with the 2-hydroxy group of glycerol.


A (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid in which the two stereocentres at positions 14 and 15 both have R-configuration.


15-oxoprostaglandin F2alpha

A prostaglandin Falpha obtained by formal oxidation of the 15-hydroxy group of prostaglandin F2alpha.


A HETE having a (12R)-hydroxy group and (5Z)-, (8Z)-, (10E)- and (14Z)-double bonds.


An HETE having a 9-hydroxy group and (5E)-, (7Z)-, (11Z)- and (14Z)-double bonds.


20,20-dihydroxyleukotriene B4

A leukotriene that is leukotriene B4 in which two of the methyl hydrogens at position 20 have been replaced by hydroxy groups.


prostaglandin G2 2-glyceryl ester

A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin G2 with the 2-hydroxy group of glycerol.


An icosanoid that is (6E,8Z,10E,14Z)-icosatetraenoic acid substituted at positions 5 and 12 by oxo and hydroxy groups respectively.


An optically active form of 15-HETE having 15(S)-configuration..


15-deoxy-Δ-12,14-prostaglandin J2

A prostaglandin J derivative comprising prostaglandin J2 lacking the 15-hydroxy group and having C=C double bonds at the 12- and 14-positions.


leukotriene B5

A leukotriene composed of (6Z,8E,10E,14Z,17Z)-icosapentaenoic acid carrying (5S)- and (12R)-hydroxy substituents.


2,3,4,5-tetranor-thromboxane B1

A monocarboxylic acid that is thromboxane B1 which is lacking four methylenes in the carboxyalkyl chain. It is a urinary metabolite of thromboxane B2.


An epoxy(hydroxy)icosatrienoic acid that is (8Z,11Z,14Z)-icosatrienoic acid having the epoxide group across positions 5-6 and the hydroxy substituent located at position 20.


A trihydroxyicosatrienoic acid that is (5Z,8Z,13E)-icosatrienoic acid in which the three hydroxy groups are located at positions 11, 12 and 15.


unoprostone isopropyl

The isopropyl ester of unoprostone.


20-oxoleukotriene B4

A leukotriene that is leukotriene B4 bearing an additional oxo substituent at position 20.


A prostanoid that is 18,19,20-trinor-prostaglandin D2 in which one of the terminal methyl hydrogens has been replaced by a phenyl group.


12-oxo-20-hydroxyleukotriene B4

A member of the class of leukotrienes that is leukotriene B4 in which the hydroxy group at position 12 has been oxidised to the corresponding ketone and one of the methyl hydrogens at position 20 replaced by a hydroxy group.


prostaglandin J3

A member of the class of prostaglandins J that is (5Z,9Z,13E,17Z)-prostatetraenoic acid carrying hydroxy and oxo substituents at positions 11 and 15 respectively. An intermediate of specialised proresolving mediators


An 11,12-EET in which the epoxy moiety has 11R,12S-configuration.


6-epi-lipoxin A4

A C20 hydroxy fatty acid having (5S)-, (6S)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.


A prostaglandin Falpha obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin F2alpha.


2,3,4,5-tetranor-prostaglandin FM

A prostanoid that is prostaglandin E2-UM in which the oxo group at position 9 has been reduced to the corresponding alcohol (alpha-configuration).


A prostanoid-LPC that is the ammonium betaine of a 2-(prostaglandin H2)-sn-glycero-3-phosphocholine arising from deprotonation of the phosphate OH group; major species at pH 7.3.


prostaglandin F2beta

A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is the 9beta-hydroxy epimer of prostaglandin F2alpha.


A trienoic fatty acid consisting of (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid having additional (7R)-hydroxy- and (5S,6S)-epoxy groups.


aspirin triggered lipoxin A4

A C20 hydroxy polyunsaturated fatty acid having (5S)-, (6R)- and (15R)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.


THROMBOXANE B2

A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.


An epoxy(hydroxy)icosatrienoic acid that is (5Z,8Z,14Z)-icosatrienoic acid having the epoxide group across positions 11-12 and the hydroxy substituent located at position 20.


A member of the class of prostaglandins Falpha that is 15-oxo-prostaglandin F2alpha in which the methyl group has been oxidised to the corresponding carboxylic acid and in which the double bond at positions 13-14 has been reduced to a single bond.


nonclassic icosanoid

Any biologically active signalling molecule made by oxygenation of C20 fatty acids other than the classic icosanoids (the leukotrienes and the prostanoids).


gadelaidic acid

An icosenoic acid having a trans- double bond at position 9.


A hydroperoxy fatty acid that is (8Z,10E,14Z)-icosatrienoic acid in which the hydroperoxy group is located at the 12(S)-position.


An epoxy(hydroxy)icosatrienoic acid consisting of (5Z,9E,14Z)-icosa-5,9,14-trienoic acid having additional (8R)-hydroxy- and (11S,12S)-epoxy groups.


DHET

An icosanoid obtained by formal dihydroxylation across one of the double bonds of arachidonic acid.


An optically active form of 15-HETE having 15(R)-configuration.


A leukotriene that is 10,11-dihydroleukotriene B4 in which two of the methyl hydrogens at position 20 have been replaced by hydroxy groups.


A 9-HPETE in which the 9-hydroxy group has S stereochemistry.


19-hydroxyprostaglandin I2

A prostaglandin I that consists of prostaglandin I1 carrying an additional hydroxy substituent at position 19.


(Z)-icos-13-enoic acid

An icosenoic acid having a cis- double bond at position 13.


A member of the class of prostaglandins J that consists of prosta-5,9,13-trien-1-oic acid substituted by an oxo group at position 11 and a hydroxy group at position 15 (the 5Z,13E,15S stereoisomer).


An epoxy(hydroxy)icosatrienoic acid that is (5Z,8Z,12E)-icosatrienoic acid having the epoxide group across positions 14-15 and the hydroxy substituent located at position 11.


13,14-dihydro-15-oxolipoxin A4

A C20 hydroxy fatty acid obtained by formal hydrogenation across the 13,-14-double bond of 15-oxolipoxin A4.


prostaglandin B3

A member of the class of prostaglandins A that is prosta-5,8(12),13,17-tetraen-1-oic acid carrying oxo and hydsroxy substituents at positions 9 and 15 respectively (the 5Z,13E,15S,17Z-stereoisomer).


A HETE having a (12S)-hydroxy group and (5Z)-, (8Z)-, (10E)- and (14Z)-double bonds.


12-epi LTB4

A leukotriene that is the 12S-isomer of leukotriene B4.


A member of the class of prostaglandins J that is prosta-5,9,12-trien-1-oic acid carrying oxo and hydsroxy substituents at positions 11 and 15 respectively (the 5Z,12E,15S-stereoisomer).


11-dehydro-thromboxane B2

A thromboxane obtained by formal oxidation of the hemiacetal hydroxy function of thromboxane B2.


A hydroperoxy(hydroxy)icosatetraenoic acid that is (6E,8Z,11Z,13E)-icosatetraenoic acid in which the hydroxy and hydroperoxy substituents are located at positions 5S and 15S respectively.


An EET obtained by formal epoxidation of the 14,15-double bond of arachidonic acid.


prostaglandin F2alpha 2-glyceryl ester

A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin F2alpha with the 2-hydroxy group of glycerol.


A HPETE in which the hydroxy group is located at position 9 with the four double bonds at positions 5, 7, 11 and 14 (the 5Z,7E,11Z,14Z geoisomer).


prostaglandin D3

A member of the class of prostaglandins D that is prosta-5,13,17-trien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,13E,15S,17Z-stereoisomer).


A polyunsaturated fatty acid that is (6E,8Z,11Z,14Z,16E)-icosapentaenoic acid substituted at positions 5 and 18 by hydroperoxy and hydroxy groups respectively (the 5S, 18S-stereoisomer).


A HPETE that consists of (5Z,8Z,11Z,13E)-icosatetraenoic acid in which the hydroperoxy group is located at position 15.


An icosanoid that is any icosatetraenoic acid bearing hydroxy and hydroperoxy substituents. An oxidation product of icosatetraenoic acid metabolism.


5,8,11-icosatriynoic acid

A C20 polyunsaturated fatty acid having three triple bonds in the 5-, 8- and 11-positions.


A bis(hydroperoxy)icosatetraenoic acid that is (5Z,8Z,10E,12E)-icosatetraenoic acid carrying two hydroperoxy substituents at positions 14 and 15 (the 14R,15S-stereoisomer).


A HETE that is arachidonic acid carrying a hydroxy substituent at position 7.


18-carboxy-19,20-dinor-leukotriene E4

An icosanoid that is leukotriene E4 in which two methylene groups are removed from the carboxyalkyl chain attached to the non-conjugated double bond.


An 8,9-EET in which the epoxy moiety has 8S,9R-configuration.


An epoxy(hydroxy)icosatrienoic acid consisting of (5Z,9E,14Z)-icosa-5,9,14-trienoic acid having additional (8R)-hydroxy- and (11R,12R)-epoxy groups.


10,11-dihydro-12-oxoleukotriene B4

A hydroxy polyunsaturated fatty acid that is (6Z,8E,14Z)-icosatrienoic acid carrying hydroxy and oxo substituents at positions 5 and 12 respectively.


A 16-carboxy-Delta(13)-17,18,19,20-tetranor-leukotriene E4 in which the double bond at position 13-14 has E-configuration.


A prostanoid that is 2,3-dinor-6-oxo-prostaglandin F1alpha in which a hydrogen at position 19 is replaced by a hydroxy group.


A HETE that is arachidonic acid carrying a hydroxy substituent at position 10.


A DiHETE that is (6E,8Z,12E,14Z)-icosatetraenoic acid in which the two hydroxy substituents are placed at the 5S- and 11R-positions.


eoxin A4

An oxylipin that is the (14S,15S)-epoxy derivative of (5Z,8Z,10E,12E)-icosa-5,8,10,12-tetraenoic acid.


2,3-dinor-6-oxoprostaglandin F1alpha

A prostanoid that is prostaglandin F1alpha lacking two methylenes in the carboxyalkyl chain and bearing an oxo group at the 6-position.


A prostanoid that is prostaglandin E2 in which both of the hydrogens at position 16 have been replaced by methyl groups. A synthetic analogue of prostaglandin E2, it is a potent inhibitor of pancreatic function and growth of experimental tumors. It also protects the gastric mucosa, prevents ulceration, and promotes the healing of peptic ulcers.


A (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid in which the two stereocentres at positions 14 and 15 both have S-configuration.


A polyunsaturated fatty acid consisting of (7E,9E,11Z,14Z,16E)-icosapentaenoic acid carrying additional 18-hydroxy and (5S,6S)-epoxy groups.


A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as (9S,11R)-epidioxy-(15S)-hydroperoxy-(5Z,13E)-prostadienoyl.


19-hydroxyleukotriene B4

A leukotriene that is leukotriene B4 carrying an additional hydroxy substituent at position 19.


13,14-dihydro-15-oxo-prostaglandin E2

The 13,14-dihydro derivative of 15-oxo-prostaglandin E2.


A DiHETE that is (5Z,8Z,10E,12E)-icosatetraenoic acid carrying two hydroxy substituents at positions 14 and 15 (the 14R,15S-stereoisomer).


An EET obtained by formal epoxidation of the 8,9-double bond of arachidonic acid.


epoxy(hydroxy)icosatrienoic acid

A nonclassic icosanoid that consists of any icosatrienoic acid carrying epoxy and hydroxy substituents.


A HETE having an (8S)-hydroxy group and (5Z)-, (9E)-, (11Z)- and (14Z)-double bonds.


A 16-HETE in which the chiral centre at position 16 has S-configuration.


A hydroperoxy fatty acid that is (5Z,8Z,10E)-icosatrienoic acid in which the hydroperoxy group is located at the 12(S)-position.


An 11-HETE in which the chiral centre at position 11 has S-configuration.


A HETE that is arachidonic acid carrying a hydroxy substituent at position 13.


prostaglandin H2 2-glyceryl ester

A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin H2 with the 2-hydroxy group of glycerol.


An icosatetraenoic acid in which the double bonds are located at the 6-7, 8-9, 11-12, and 14-15 positions and have E, Z, Z, and Z geometry, respectively, and in which the pro-S hydrogen is substituted by a hydroperoxy group.


Delta(6)-trans-12-epi-leukotriene B4

A leukotriene that is the 6-trans,12S-isomer of leukotriene B4.


A  clavulone that is a chlorinated prostanoid isolated from marine corals.


A HPETE that consists of (6E,8Z,11Z,14Z)-icosatetraenoic acid in which the hydroperoxy group is located at position 5.


A HETE having a (5S)-hydroxy group and (6E)-, (8Z)-, (11Z)- and (14Z)-double bonds.


6-oxoprostaglandin E1

A prostaglandin E that is prostaglandin E1 bearing a keto substituent at the 6-position.


A HETE having a (9S)-hydroxy group and (5Z)-, (7E)-, (11Z)- and (14Z)-double bonds.


A DiHETE that is 5-HETE carrying an additional hydroxy substituent at position 20.


12-oxo-6-trans-leukotriene B4

A leukotriene consisting of 6-trans-leukotriene B4 having a 12-keto group in place of the 12-hydroxy group.


A 17(18)-EpETE in which the epoxy group has (17R,18S)-configuration.


A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oyl


A prostaglandin Falpha obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin F1alpha.


bis(hydroperoxy)icosatetraenoic acid

An icosanoid that consists of any icosatetraenoic acid carrying two hydroperoxy substituents at unspecified positions.


prostaglandin H3

A member of the class of prostaglandins H that is 9,11-epidioxyprosta-5,13,17-trienoic acid carrying an additional hydroxy substituent at the 15S-position.


A hydroperoxy fatty acid that is (8Z,10E,14Z)-icosatrienoic acid in which the hydroperoxy group is located at position 12.


15-deoxy-Delta(12,14)-prostaglandin D2

A prostaglandin D derivative that is prostaglandin D2 lacking the 15-hydroxy group and having C=C double bonds at positions 12(13) and 14(15).


A leukotriene compound having double bonds in the 7-, 9-, 11- and 14-positions and 5(S)- and 6(S)-hydroxy substituents.


10,11-dihydroleukotriene B4

A leukotriene obtained by formal dehydrogenation of the 10,11-double bond in leukotriene B4.


An epoxy(hydroxy)icosatrienoic acid consisting of (5Z,8Z,11Z)-icosa-5,9,14-trienoic acid having additional (13R)-hydroxy- and (14S,15S)-epoxy groups.


A HETE that is icosa-5,8,10,14-tetraenoic acid substituted by a hydroxy group at position 12. It is a metabolite of arachidonic acid.


An HETE having a 8-hydroxy group and (5Z)-, (9E)-, (11Z)- and (14Z)-double bonds.


An epoxy(hydroxy)icosatrienoic acid that is (5Z,11Z,14Z)-icosatrienoic acid having the epoxide group across positions 8-9 and the hydroxy substituent located at position 20.


thromboxane A2

A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation.


A trihydroxyicosatrienoic acid that is (5Z,8Z,11Z)-icosatrienoic acid in which the three hydroxy groups are located at positions 13, 14 and 15.


A leukotriene that is the (5S,6S)-epoxy derivative of (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid.


An EpETE obtained by formal epoxidation of the 8,9-double bond of all-cis-5,8,11,14,17-icosapentaenoic acid.


20-hydroxylipoxin B4

A member of the class of lipoxins that is lipoxin B4 carrying an additional hydroxy substituent at position 20.


prostaglandin H1

A member of the class of prostaglandins H that is prostaglandin H2 lacking the double bond at position 5.


13,14-dihydroprostaglandin F2alpha

A prostaglandins Falpha that is prost-5-en-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.


15-oxolipoxin A4

A C20 hydroxy fatty acid having (5S)- and (6R)- -hydroxy groups as well as a 15-oxo group and (7E)- (9E)-, (11Z)- and (13E)-double bonds.


A polyunsaturated fatty acid that is (6E,8Z,11Z,14Z,16E)-icosapentaenoic acid substituted at positions 5 and 18 by hydroperoxy and hydroxy groups respectively (the 5S, 18R-stereoisomer).


A HETE having a (19S)-hydroxy group and all-cis double bonds at positions 5, 8, 11 and 14.


A HETE that consists of arachidonic acid bearing an additional hydroxy substituent at position 17.


trihydroxyicosatrienoic acid

A nonclassic icosanoid that consists of any icosatrienoic acid carrying three hydroxy substituents.


A HPETE that is (5Z,8Z,10E,12R,14Z)-icosa-5,8,10,14-tetraenoic acid with the hydroperoxy group located at position 12 (the R-enantiomer).


A trihydroxyicosatrienoic acid that is (5Z,8Z,12E)-icosatrienoic acid in which the three hydroxy groups are located at positions 11, 14 and 15.


A leukotriene that is (5S,7E,9E,12R,14Z)-5,12-dihydroxyicosa-7,9,14-trienoic acid to which a glutathionyl group is attached at position 6 via a sulfide linkage.


prostaglandin F1alpha alcohol

A member of the class of prostaglandins Falpha that is prostaglandin F1alpha in which the carboxy group has been reduced to the corresponding primary alcohol.


A 5(),6(S)-epoxy-18-hydroxy-(7E,9E,11Z,14Z,16E)-icosapentaenoic acid in which the 18-hydroxy group has S-configuration.


Any isoprostane derived from the non-enzymatic, free radical oxidation of arachidonic acid.


carbocyclic thromboxane A2

A member of the class of thromboxanes that is thromboxane A2 in which the bridging oxygen has been replaced by a methylene group.


name: 13,14-dihydro-15-keto PGF2alpha isopropyl ester


prostaglandin I2 2-glyceryl ester

A 2-monoglyceride obtained by formal condensation of the carboxy group of prostaglandin I2 with the 2-hydroxy group of glycerol.


A hydroperoxyicosatrienoic acid that is (8Z,12E,14Z)-icosatrienoic acid in which the hydroperoxy substituent is located at position 11.


The (R)-enantiomer of 8-HPETE.


thromboxane B3

A member of the class of thromboxanes B that is (5Z,13E,17Z)-thromboxa-5,13,17-trien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.


A hydroperoxy fatty acid that is (5Z,8Z,10E,14Z,17Z)-icosapentaenoic acid in which the hydroperoxy group is located at the 12-position.


A hydroperoxyicosatrienoic acid that is (9E,11Z,14Z)-icosatrienoic acid in which the hydroperoxy substituent is located at position 8R.


A DiHETE that consists of 6E,8Z,11Z,13E-icosatetraenoic acid having the two hydroxy groups located at positions 5 and 15.


A 13-hydroxy-14,15-epoxy-(5Z,8Z,11Z)-icosatrienoic acid in which the three chiral centres at positions 13, 14 and 15 all have S-configuration.


20-hydroxyprostaglandin A1

A prostaglandin A derivative that is prostaglandin A1 in which one of the methyl hydrogens at position 20 has been replaced by a hydroxy group.


hydroperoxyicosapentaenoic acid

A hydroperoxy polyunsaturated fatty acid that is any icosapentaenoic fatty acid carrying a single hydroperoxy substituent.


EpETE

An epoxy fatty acid obtained by formal epoxidation of one of the double bonds of any icosapentaenoic acid.


2,3-dinor-prostaglandin E2

A prostanoid that is prostaglandin E2 lacking two methylenes in the carboxyalkyl chain.


A prostanoid that is 18,19,20-trinor-prostaglandin E2 in which one of the terminal methyl hydrogens has been replaced by a phenyl group.


A HETE that consists of arachidonic acid bearing a hydroxy substituent at position 18.


hydroperoxyicosatrienoic acid

A hydroperoxy polyunsaturated fatty acid that is any icosatrienoic fatty acid carrying a single hydroperoxy substituent.


An 8,9-EET in which the epoxy moiety has 8R,9S-configuration.


A dihydroxyicosatetraenoic acid (7E,9E,11Z,14Z)-icosatetraenoic acid in which the two hydroxy substituents are located at positions 5S and 6R.


A C20 hydroxy fatty acid having (5S)-, (14R)- and (15S)-hydroxy groups as well as (6E)- (8Z)-, (10E)- and (12E)-double bonds.


A hydroperoxyicosapentaenoic acid that is (5Z,8Z,11Z,14Z,16E)-icosapentaenoic acid in which the pro-R hydrogen at position 18 has been replaced by a hydroperoxy group. One of the two stereoisomers formed when acetylated COX2 oxidises the omega-3 fatty acid EPA.


A DiHETE that is 8-HETE carrying an additional hydroxy substituent at position 20.


15-deoxy-Delta(12,14)-prostaglandin A2

A prostaglandin A derivative that is prostaglandin A2 lacking the 15-hydroxy group and having C=C double bonds at positions 12(13) and 14(15).


Delta(12)-prostaglandin J3

A member of the class of prostaglandins J that is (5Z,9Z,12E,17Z)-prostatetraenoic acid carrying hydroxy and oxo substituents at positions 11 and 15 respectively. An intermediate of specialised proresolving mediators and potent anti-leukemic agent.


A member of the class of lipoxins that is (7E,9E,11Z,13E,17Z)-icosapentaenoic acid carrying three hydroxy substituents at positions 5, 6, and 15R.


A 13-HETE in which the stereocentre at position 13 has S-configuration.


prostaglandin D2 2-glyceryl ester

A 2-monoglyceride resulting from the condensation of the carboxy group of prostaglandin D2 with the 2-hydroxy group of glycerol.


A HETE that consists of arachidonic acid bearing a hydroxy substituent at position 20.


An icosanoid that is (6E,8Z,11Z,14Z,17Z)-icosapentaenoic acid substituted at positions 5 and 20 by hydroxy groups.


20-hydroxyprostaglandin E2

A prostaglandin E derivative that is prostaglandin E2 in which one of the methyl hydrogens at position 20 has been replaced by a hydroxy group.


19-hydroxyprostaglandin H1

A prostaglandin H that consists of prostaglandin H1 bearing an additional hydroxy substituent at position 19.


A DiHETE that is 12-HETE carrying an additional hydroxy substituent at position 20.


prostaglandin F2alpha 1-ethanolamide

An N-acylethanolamine compound formed by a condensation of prostaglandin F2alpha and ethanolamine.


17-icosenoic acid

An icosenoic acid having a double bond at position 17.


A DiHETE that is (6E,8Z,11Z,13E)-icosatetraenoic acid in which the two hydroxy substituents are placed at the 5S- and 15R-positions.


A 16-HETE in which the chiral centre at position 16 has R-configuration.


A 14,15-EET in which the epoxy moiety has 14R,15S-configuration.


An 11,12-EET in which the epoxy moiety has 11S,12R-configuration.


11-epi-prostaglandin F2alpha

The prostaglandin F that is the 11-epimer of prostaglandin F2alpha.


A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as (9S,11R)-epidioxy-(15S)-hydroperoxy-(5Z,13E)-prostadienoyl.


A HPETE that is (5Z,8Z,11Z,13E,15R)-icosa-5,8,11,13-tetraenoic acid with the hydroperoxy group located at position 15 (the R-enantiomer).


EET

An icosanoid obtained by formal epoxidation of one of the double bonds of arachidonic acid.


An icosanoid that is (6E,8Z,11Z,14Z,16E)-icosa-6,8,11,14,16-pentaenoic acid substituted at positions 5S and 18 by hydroperoxy and hydroxy groups respectively.


20-hydroxyprostaglandin E1

A prostaglandin E derivative that is prostaglandin E1 in which one of the methyl hydrogens at position 20 has been replaced by a hydroxy group.


6-oxoprostaglandin F1alpha

A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.


HETE

Any monohydroxylated icosanoid having four double bonds.


A 17(18)-EpETE in which the epoxy group has (17S,18R)-configuration.


A HETE that consists of arachidonic acid bearing a hydroxy substituent at position 19.


20-oxoleukotriene E4

A leukotriene that is leukotriene E4 in which the terminal methyl grop has been oxidised to the corresponding aldehyde


icosenoic acid

An icosanoid comprising icosanoic acid having one C=C bond at any position.


An icosanoid that is leukotriene E3 in which the terminal octyl group is replaced by a carboxymethyl group.


The (S)-enantiomer of 15-HPETE.


An icosanoid that is (6E,8Z,11Z,13E)-icosa-6,8,11,13-tetraenoic acid substituted at positions 5 and 15 by hydroperoxy and hydroxy groups respectively.


prostaglandin E2 1-glyceryl ester

A 1-monoglyceride resulting from the condensation of the carboxy group of prostaglandin E2 with the 1-hydroxy group of glycerol.


A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as (9S,11R)-epidioxy-(15S)-hydroxy-(5Z,13E)-prostadienoyl.


15-dehydroprostaglandin A1

A member of the class of prostaglandins A obtained by oxidation of the 15-hydroxy group of prostaglandin A1 to the corresponding ketone.


A HPETE in which the hydroperoxy group is located at position 8S and the four double bonds at position 5, 9, 11 and 14 (the 5Z,9E,11Z,14Z-geoisomer).


The (5Z,8Z,10E,14Z)-stereoisomer of 12-HETE.


prostanoid

The family of natural prostaglandins and prostaglandin-like compounds including prostacyclins and thromboxanes.


A prostaglandin Falpha that is prostaglandin F1alpha bearing keto substituents at positions 6 and 15.


An icosanoid that is leukotriene E4 in which the isolated double bond has migrated into conjugation with the triene moiety and in which four methylene groups have been lost from the resulting carboxyalkyl chain.


A 12-HPEPE in which the hydroperoxy group at positions 12 has S-configuration.


13,14-dihydrolipoxin A4

A trienoic fatty acid obtained by formal hydrogenation across the 13,14-double bond of lipoxin A4.


thromboxane B1

A thromboxane B that is thromboxane B2 in which the double bond at position 5-6 has been reduced to a single bond.


LEUKOTRIEN E4

A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and an L-cystein-S-yl group at position 6 (6R).


20-carboxyleukotriene E4

A leukotriene that is leukotriene E4 in which the terminal methyl grop has been oxidised to the corresponding carboxylic acid.


A HETE that consists of arachidonic acid bearing an additional hydroxy substituent at position 16.


An epoxy(hydroxy)icosatrienoic acid that is (5Z,8Z,11Z)-icosatrienoic acid having the epoxide group across positions 14-15 and the hydroxy substituent located at position 20.


An EET obtained by formal epoxidation of the 11,12-double bond of arachidonic acid.


dihydroxyicosatetraenoic acid

A hydroxy fatty acid that is any eicosatetraenoic acid bearing two hydroxy substituents.


prostaglandin G1

A member of the class of prostaglandins G that is 9alpha,11alpha-epidioxy-13-trans-prostenoic acid carrying an additional hydroperoxy substituent at the 15S-position.


A DiHETE that is (6E,8Z,11Z,13E)-icosatetraenoic acid in which the two hydroxy substituents are placed at the 5S- and 15S-positions.


An icosanoid that is (6E,8Z,11Z,13E)-icosatetraenoic acid substituted at positions 5 and 15 by oxo and hydroxy groups respectively.


A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oyl


A polyunsaturated fatty acid consisting of (7E,9E,11Z,14Z,16E)-icosapentaenoic acid carrying additional (18R)-hydroxy and (5S,6S)-epoxy groups.


A (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoic acid in which the two stereocentres at positions 11 and 12 both have R-configuration.


A HETE having a 5-hydroxy group and (6E)-, (8Z)-, (11Z)- and (14Z)-double bonds.


isoprostane

Any icosanoid with a prostaglandin-like structure formed in vivo by non-enzymatic free radical-catalysed reactions involving peroxidation of essential fatty acids (mainly arachidonic acid but also other fatty acids with 3 or more double bonds). Isoprostanes are abundant in tissues and fluids and have immunomodulating activity. Their concentration is dependent on the amount of oxidative stress and may be upregulated in certain diseases such as cancer, cardiovascular and neurological disorders.


5,6-epoxyeicosatrienoic acid

An EET obtained by formal epoxidation of the 5,6-double bond of arachidonic acid.


prostaglandin A3

A member of the class of prostaglandins A that is prosta-5,10,13,17-tetraen-1-oic acid carrying oxo and hydroxy substituents at positions 9 and 15 respectively (the 5Z,13E,15S,17Z-stereoisomer).


A (5Z,11Z,14Z)-8,9-dihydroxyicosatrienoic acid in which the two stereocentres at positions 8 and 9 both have R-configuration.


A (5Z,11Z,14Z)-8,9-dihydroxyicosatrienoic acid in which the two stereocentres at positions 8 and 9 both have S-configuration.


A 9-HPETE in which the 9-hydroxy group has R stereochemistry.


prostaglandin C2

A member of the class of prostaglandins C that is prosta-5,11,13-trien-1-oic acid carrying oxo and hydroxy substituents at positions 9 and 15 respectively (the 5Z,13E,15S-stereoisomer).


bimatoprost (free acid form)

A member of the class of prostaglandins Falpha that is latanoprost free acid with a double bond at position 13.


A hydroperoxyicosatrienoic acid that is (8Z,11Z,13E)-icosatrienoic acid in which the pro-S hydrogen at position 15 has been replaced by a hydroperoxy group.


A C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.


A DHET obtained by formal dihydroxylation across the 11,12-double bond of arachidonic acid.


20-hydroxy-6-trans-leukotriene B4

A member of the class of leukotrienes that is 6-trans-leukotriene B4 bearing an additional hydroxy substituent at position 20.


nonacosanoic acid

A very long-chain fatty acid comprising of 29 carbon atoms.


An EpETE obtained by formal epoxidation of the 11,12-double bond of all-cis-5,8,11,14,17-icosapentaenoic acid.


A 5-hydroperoxy-15-HETE stereoisomer that has 5S,15S configuration.


18-hydroxycarbocyclic thromboxane A2

A member of the class of thromboxanes that is carbocyclic thromboxane A2 carrying an additional hydroxy substituent at position 18.


prostaglandin E2-UM

A prostanoid that is prostaglandin E2 in which the acyclic hydroxy group has been oxidised to the corresponding ketone, the methyl group has been oxidised to the corresponding carboxylic acid and the 6-carboxyhexenyl group has been oxidatively cleaved to a 2-carboxyethyl group. It is the major urinary metabolite of prostaglandin E2.


An epoxy(hydroxy)icosatrienoic acid that is (5Z,8Z,11Z)-icosatrienoic acid having the epoxide group across positions 14-15 and the hydroxy substituent located at position 13.


18-hydroxyleukotriene B4

A leukotriene that is leukotriene B4 carrying an additional hydroxy substituent at position 18.


A leukotriene that is 10,11-dihydroleukotriene B4 in which the three methyl hydrogens at position 20 have been replaced by hydroxy groups.


15-dehydro-prostaglandin D2

The 15-dehydro derivative of prostaglandin D2.


An HETE that is (5Z,7E,11Z,14Z)-icosa-5,7,11,14-tetraenoic acid in which the hydroxy group is located at position 9.


A DHET obtained by formal dihydroxylation across the 5,6-double bond of arachidonic acid.


An epoxy(hydroxy)icosatrienoic acid consisting of (5Z,8Z,14Z)-icosa-5,9,14-trienoic acid having additional (10R)-hydroxy- and (11S,12S)-epoxy groups.


hydroperoxy(epoxy)icosatrienoic acid

An icosanoid derived from hydroperoxidation and epoxidation across one of the double bonds of arachidonic acid.


A hydroperoxy fatty acid that is (14S,15R)-epoxy-(5Z,9E,11Z)-icosatrienoic acid in which the hydroperoxy group is located at position 8S.


15-deoxy-Delta(12,14)-prostaglandin J3

A prostaglandin J derivative comprising prostaglandin J3 lacking the 15-hydroxy group and having C=C double bonds at the 12- and 14-positions. An intermediate of specialised proresolving mediators


prostaglandin H2 1-ethanolamide

An N-acylethanolamine compound formed by a condensation of prostaglandin H2 and ethanolamine.


prostaglandin F3alpha

A prostaglandin Falpha that is prosta-5,13,17-trien-1-oic acid carrying three hydroxy substituents at positions 9alpha, 11alpha and 15.


12-dehydro-leukotriene B4

A long-chain fatty acid consisting of leukotriene B4 having a 12-keto group in place of the 12-hydroxy group.


8-epi-prostaglandin E2

A prostanoid that is prostaglandin E2 having inverted stereochemistry at the 8-position.


PROSTAGLANDIN B1

A member of the class of prostaglandins B that is prosta-8(12),13-dien-1-oic acid carrying oxo and hydroxy substituents at positions 9 and 15 respectively (the 13E,15S-stereoisomer).


An icosanoid that is (6E,8Z,11Z,14Z,17Z)-icosapentaenoic acid carrying an oxo substituent at position 5. An intermediate of specialised proresolving mediators.


A HETE having an (8R)-hydroxy group and (5Z)-, (9E)-, (11Z)- and (14Z)-double bonds.


A hydroperoxy fatty acid that is (14S,15R)-epoxy-(5Z,8Z,10E)-icosatrienoic acid in which the hydroperoxy group is located at position 12S.


A prostanoid that is prostaglandin F2alpha  which is lacking two methylenes in the carboxyalkyl chain and in which the hydroxy group at position 15 has been oxidised to the corresponding ketone.


An EpETE obtained by formal epoxidation of the 14,15-double bond of all-cis-5,8,11,14,17-icosapentaenoic acid.


15-epi-lipoxin B4

A C20 hydroxy fatty acid having (5S)-, (14R)- and (15R)-hydroxy groups as well as (6E)- (8Z)-, (10E)- and (12E)-double bonds.


A 2-monoglyceride resulting from the condensation of the carboxy group of 15-deoxy-Delta(12,14)-prostaglandin J2 with the  hydroxy group at position 2 of glycerol.


20,20,20-trihydroxyleukotriene B4

A leukotriene that is leukotriene B4 in which the three methyl hydrogens at position 20 have been replaced by hydroxy groups.


prostaglandin G3

A member of the class of prostaglandins G that is 9,11-epidioxyprosta-5,13,17-trienoic acid carrying an additional hydroperoxy substituent at the 15S-position.


19-hydroxycarbocyclic thromboxane A2

A member of the class of thromboxanes that is carbocyclic thromboxane A2 carrying an additional hydroxy substituent at position 19.


An icosanoid that is (5Z,9E,14Z)-icosa-5,9,14-trienoic acid carrying four hydroxy substituents at positions 8, 11, 12 and 20. An intermediary metabolite from the 12(R)-lipoxygenase pathway.


leukotriene

Any icosanoid from that family of C20 polyunsaturated fatty acids and their derivatives generated by leukocytes from arachidonic acid, each member having four double bonds of which three are conjugated.


An 18-HETE in which the 18-hydroxy group has R-configuration.


A 14,15-EET in which the epoxy moiety has 14S,15R-configuration.


A leukotriene with formula C23H39NO6S that results from the metabilism of leukotriene B4 by human keratinocytes.


HPETE

Mono-hydroperoxy (e)icosatetraenoic acids (HPETEs) are the primary products of lipoxygenase-catalysed oxygenation of arachidonic acid.


A member of the class of resolvins that is (6Z,8E,10E,14Z,16E)-icosapentaenoic acid carrying three hydroxy substituents at positions 5, 12, and 18R.


15-ketoprostaglandin F1alpha

A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 15-position. It is the initial metabolite of prostaglandin F1alpha via 15-hydroxyprostaglandin dehydrogenase.


(17Z)-icosenoic acid

A 17-icosenoic acid in which the double bond adopts cis-configuration.


(18S)-hydroperoxyicosapentaenoic acid

A hydroperoxyicosapentaenoic acid that is an icosapentaenoic acid in which the pro-S hydrogen at position 18 has been replaced by a hydroperoxy group.


prostaglandin F2alpha 1-glyceryl ester

A 1-monoglyceride resulting from the condensation of the carboxy group of prostaglandin F2alpha with the 1-hydroxy group of glycerol.


A DiHETE consisting of arachidonic acid having the two hydroxy substituents located at position 17 and 18.


19-hydroxythromboxane A2

A thromboxane A that is thromboxane A2 carrying an additional hydroxy substituent at position 19.


An icosanoid that is any icosapentaenoic acid bearing hydroxy and hydroperoxy substituents. An oxidation product of icosapentaenoic acid metabolism.


An icosanoid that is leukotriene E4 in which the non-conjugated double bond has been reduced to a single bond and four methylene groups have been lost from the resulting carboxyalkyl chain.


A DHET obtained by formal dihydroxylation across the 14,15-double bond of arachidonic acid.


18-oxoresolvin E1

A nonclassic icosanoid that is (6Z,8E,10E,14Z,16E)-icosa-6,8,10,14,16-pentaenoic acid carrying two hydroxy groups at positions 5 and 12 as well as an oxo group at position 18.


13,14-dihydro-15-oxoprostaglandin E1

A prostaglandin E obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin E1.


A leukotriene composed of (6E,8Z,10E,14Z)-icosatetraenoic acid having 5S- and 12R-hydroxy substituents.


An EpETE that is (5Z,9Z,11Z,14Z)-icosatetraenoic acid in which the epoxide function is located across positions 8 and 9.


The (S)-enantiomer of 12-HPETE.


11,12-dihydro-12-oxoleukotriene C4

A leukotriene  that is (5S,7E,9E,14Z)-5-hydroxy-12-oxoicosa-7,9,14-trienoic acid to which a glutathionyl group is attached at position 6 via a sulfide linkage.


A HETE that is (5Z,8Z,11Z,13E)-15-hydroxyicosa-5,8,11,13-tetraenoic acid bearing a hydroxy substituent at position 15.


A (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoic acid in which the two stereocentres at positions 11 and 12 both have S-configuration.


A 13-hydroxy-14,15-epoxy-(5Z,8Z,11Z)-icosatrienoic acid in which the chiral centres at positions 14 and 15 have R- and S-configuration respectively while that at position 13 remains unspecified.


Brown-Vialetto-van Laere syndrome 1

description: Any Brown-Vialetto-van Laere syndrome in which the cause of the disease is a mutation in the SLC52A3 gene.


Pelvic girdle amyotrophy

description: Atrophy of the muscles of the pelvic girdle (also known as hip girdle), i.e., the gluteal muscles, the lateral rotators, the adductors, the psoas major and the iliacus muscle.


Pelvic girdle muscle atrophy

description: Muscular atrophy affecting the muscles that attach to the pelvic girdle (the gluteal muscles, the lateral rotators, adductor magnus, adductor brevis, adductor longus, pectineus, and gracilis muscles).


name: Amyotrophy of the musculature of the pelvis

description: Muscular atrophy affecting the muscles of the pelvis.


name: pro-cathepsin H glutathionylated 1 (human)

description: A pro-cathepsin H (human) that has been glutathionylated on the residue at the position equivalent to Cys-9 of the amino acid sequence represented by UniProtKB:P09668. UniProtKB:P09668, Cys-9, MOD:00234.


intravascular fasciitis

description: A rare self-limiting, rapidly growing, non-encapsulated benign neoplasm that arises from the vessels. It is characterized by the presence of plump spindle-shaped fibroblasts, multinucleated osteoclast-like giant cells, chronic inflammatory infiltrate, red blood cell extravasation, and high mitotic activity.


Leg Cramp

description: An involuntary contraction of a muscle supporting the femur.


MRG/MORF4L-binding protein

A protein that is a translation product of the human MRGBP gene or a 1:1 ortholog thereof.


name: Sin3 histone deacetylase corepressor complex component SDS3, initiator methionine removed form (human)

description: A Sin3 histone deacetylase corepressor complex component SDS3 (human) that has had the initiator methionine removed. UniProtKB:Q9H7L9, 2-328.


name: Sin3 histone deacetylase corepressor complex component SDS3, initiator methionine removed ubiquitinated form (human)

description: A Sin3 histone deacetylase corepressor complex component SDS3 (human) that has had the initiator methionine removed and that includes at least one ubiquitinated lysine. UniProtKB:Q9H7L9, 2-328, MOD:01148.


name: Stage IV Major Salivary Gland Carcinoma with Metastasis

description: Stage IV carcinoma of the major salivary glands with regional lymph nodes and/or distant metastases.


Cervical Micropapillary Adenocarcinoma

description: A rare, invasive adenocarcinoma that arises from the cervix and is characterized by a micropapillary architecture.


calcitriol 25-O-(beta-D-glucuronide)

A steroid glucosiduronic acid that is calcitriol in which the hydroxy hydrogen at position 25 has been replaced by a beta-D-glucuronyl residue.


uromodulin N-glycosylated 357 (human)

A uromodulin (human) that has been N-glycosylated at the residue equivalent to Asn-76 of the amino acid sequence represented by UniProtKB:P07911-1, in which the glycan structure is represented by GlyTouCan:G79565XA. Example: UniProtKB:P07911-1, Asn-76, MOD:00160~GNO:G79565XA.


name: laminin subunit beta-1 methylated 1 (human)

description: A laminin subunit beta-1 (human) that has been methylated on the residue at the position equivalent to Cys-1009 of the amino acid sequence represented by UniProtKB:P07942. UniProtKB:P07942, Cys-1009, MOD:00660.


name: torsin-1A-interacting protein 1 isoform h3 (human)

description: A torsin-1A-interacting protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q5JTV8-3.


name: Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8

description: Stage IVB includes: Any T, Any N, M1, Any G. M1: Distant metastasis. (AJCC 8th ed.)


name: Gastroesophageal Junction Adenocarcinoma by AJCC v8 Pathologic Stage

description: A term that refers to the pathologic staging of gastroesophageal junction adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.


name: Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8

description: Stage IIIB includes: (T2, N2, M0, Any G); (T3, N1-2, M0, Any G); (T4a, N0-1, M0, Any G). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


name: Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8

description: Stage IA includes: (T1a, N0, M0, G1); (T1a, N0, M0, GX). T1a: Tumor invades the lamina propria or muscularis mucosae. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. (AJCC 8th ed.)


name: Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8

description: Stage IIIA includes: (T1, N2, M0, Any G); (T2, N1, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)